Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Osteomyelitis of Jaw
Interventions
Amoxicillin-clavulanate 875mg/125mg q12hrs, oral clindamycin 300mg q6hrs, Levofloxacin 750mg QID
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Perianal Abscess, Anal Fistula
Interventions
Amoxicillin + Clavulanate, Ciprofloxacin + Metronidazole
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
Interventions
Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg)
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami, Florida
Conditions
Community Acquired Pneumonia in Children
Interventions
Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin, Ampicillin / Sulbactam Injection, Amoxicillin-clavulanate, Clindamycin, Cefprozil, Levofloxacin
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Months to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Urinary Tract Infection
Interventions
Fosfomycin tromethamine, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Sylmar, California • Torrance, California • Decatur, Georgia + 9 more
Conditions
Urolithiasis, UTI
Interventions
Ciprofloxacin, trimethoprim/sulfamethoxazole, No Intervention
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Terminated Phase 4 Interventional Results available

Early Antibiotics After Aspiration in ICU Patients

NCT05079620
Conditions
Aspiration, Aspiration Pneumonia
Interventions
Ceftriaxone, Amoxicillin clavulanic acid, Cefepime, Vancomycin, Levofloxacin
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Pulmonary Sarcoidosis, Lung Function
Interventions
levaquin; ethambutol; rifampin and azithromycin.
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions
Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Temple, Texas
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin for Inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more
Completed Phase 3 Interventional Results available

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

NCT00761462
Conditions
Infectious Diseases
Interventions
Ciprofloxacin, Non-quinolone antibiotic
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Months to 16 Years
Enrollment
1,029 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
66
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Corona, California + 58 more
Conditions
Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions
Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
117,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Completed Not applicable Interventional Results available

Intradialytic Drug Removal by Short-daily Hemodialysis

NCT00596167
Conditions
End Stage Renal Disease, Infection
Interventions
Intravenous antibiotics
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Colorectal Cancer, CRC
Interventions
Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Richmond, Virginia
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Drug-Induced Liver Injury
Interventions
Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,299,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Many Locations, Delaware